Related Experiment Videos
[Field studies with a new tick-borne encephalitis (TBE) vaccine]
Zentralblatt Fur Bakteriologie, Parasitenkunde, Infektionskrankheiten Und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie Und Parasitologie
|January 1, 1976
Summary
This study assessed a formalin-inactivated tick-borne encephalitis (TBE) virus vaccine. High seroconversion rates and good tolerance were observed in volunteers, indicating vaccine efficacy in endemic areas.
Area of Science:
- Virology
- Immunology
- Vaccinology
Context:
- Tick-borne encephalitis (TBE) is a significant public health concern in endemic regions.
- A formalin-inactivated TBE virus vaccine adsorbed to Alhydrogel was developed.
- Previous studies on TBE vaccines were limited in scope and population size.
Purpose:
- To evaluate the immunogenicity and safety of a formalin-inactivated TBE virus vaccine.
- To assess seroconversion rates and geometric mean titers after primary and booster vaccinations.
- To determine the vaccine's protective efficacy in a large-scale field trial in endemic areas.
Summary:
- A total of 81 volunteers received two initial doses of the TBE vaccine four weeks apart, followed by a third dose 7-9 months later.
- Seroconversion rates were 76%, 96%, and 98% after each dose, respectively, with geometric mean titers of 1:26, 1:36, and 1:44.
- The vaccine was well-tolerated, with mild systemic reactions like fever and headache reported only after the first dose. In 1974-1975, 30,000 individuals in TBE-endemic regions were vaccinated, showing circumstantial evidence of protection.
Impact:
- The study provides evidence for the efficacy and safety of a formalin-inactivated TBE virus vaccine.
- The findings support the use of this vaccine for individuals at high risk of TBE infection, such as forest workers.
- This research contributes to the control and prevention of TBE in endemic populations.